EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Last trade$0.3162
Day change+$0.0086 (+2.80%)
Day range$0.292 – $0.32
Volume1,853,194
Market cap$35M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$35.27M
Price / earnings
—
Price / book
0.33×
Price / sales
13.68×
EV / sales
-18.59×
EV / EBITDA
0.14×
Profitability
Earnings per share
-$3.01
Return on assets
-206.26%
Return on equity
-315.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.3×
Quick ratio
3.25×
Cash ratio
2.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$299.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EYPT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$756K
$507K
$696K
$620K
$966K
$5.33M
$24.45M
$11.59M
Cost of revenue
$523K
$0
$528K
$375K
$721K
$165K
$805K
$816K
Gross profit
$233K
$507K
$168K
$245K
$245K
$5.17M
$23.65M
$10.77M
Selling, general and administrative
$15.44M
$14.27M
$15.25M
$11.38M
$14.52M
$11.9M
$13.91M
$12.64M
Research and development
$81.67M
$83.61M
$72.15M
$59.21M
$47.75M
$55.5M
$58.57M
$43.37M
Total operating expenses
$97.11M
$97.89M
$87.39M
$70.59M
$62.27M
$67.4M
$72.49M
$56.01M
Operating income
-$96.88M
-$97.38M
-$87.23M
-$70.35M
-$62.03M
-$62.23M
-$48.84M
-$45.24M
Interest expense
$0
$0
$0
-$33K
$0
$0
$0
-$14K
Income before taxes
-$95.61M
-$94.47M
-$84.88M
-$67.42M
-$59.73M
-$59.33M
-$45.2M
-$41.31M
Income taxes
$0
$0
-$50K
$186K
$0
$93K
$0
$90K
Net income
-$95.61M
-$94.47M
-$84.83M
-$67.61M
-$59.73M
-$59.43M
-$45.2M
-$41.4M
Net income attributable to common shareholders
-$95.61M
-$94.47M
-$84.99M
-$67.61M
-$59.73M
-$59.43M
-$45.3M
-$41.4M
EBITDA
-$96.11M
-$96.69M
-$86.59M
-$69.65M
-$61.45M
-$61.69M
-$48.34M
-$44.77M
Basic earnings per share
-$1.07
-$1.09
-$0.99
-$0.81
-$0.85
-$0.85
-$0.65
-$0.64
Diluted earnings per share
-$1.07
-$1.09
-$0.99
-$0.81
-$0.85
-$0.85
-$0.65
-$0.64
Recent news
Company coverage with links to the original publishers.
EyePoint (EYPT) reported a quarterly loss of $1.07 per share, missing the consensus estimate of $0.88, representing a -21.59% earnings surprise. The company's stock has declined 98.1% year-to-date versus the S&P 500's 11.3% gain. Despite beating revenue estimates, the company maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions. AnaptysBio (ANAB), a peer in the Medical - Biomedical and Genetics industry, is expected to report earnings of $0.41 per share with revenues down 58% year-over-year.
Oculis Holding AG is expected to report a quarterly loss of $0.49 per share with revenues of $0.29 million for Q3 2026. However, the company has a positive Earnings ESP of +3.09% combined with a Zacks Rank #2 (Buy), suggesting it will likely beat consensus EPS estimates. The company previously delivered a significant earnings surprise of +58.33% in the last quarter.
EyePoint (EYPT) is expected to report a quarterly loss of $0.88 per share with revenues down 79.4% year-over-year for Q3 2026. However, the stock shows a positive Earnings ESP of +2.86% combined with a Zacks Rank #3, suggesting a likely earnings beat. The company has a poor track record, missing consensus estimates in the last four quarters. Liquidia Corporation (LQDA) is also discussed as an industry peer with a negative ESP and Strong Sell rating.
Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the failure of its DURAVYU drug candidate to meet primary efficacy endpoints in two Phase 3 clinical trials (LUGANO and LUCIA) for wet AMD treatment. The company's stock plummeted 66.98% on August 17, 2026, and an additional 85.28% on October 19, 2026, following the disappointing results. EyePoint announced significant cost-cutting measures including a 53% workforce reduction and termination of its wet AMD clinical program.
EyePoint announced that LUCIA, its second Phase 3 clinical trial of DURAVYU for wet AMD treatment, failed to meet its primary endpoint of non-inferiority in visual acuity versus aflibercept control. However, the drug demonstrated visual improvement and met key secondary endpoints including a 38% reduction in treatment burden and strong anatomic control. The company plans to conduct additional analyses and remains focused on its Phase 3 DME program with data expected in Q4 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.